anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

164,101-164,160 of 319,975

filter-aware
07
The slide uses a bulleted list to present key performance indicators, accompanied by a lifestyle image of the product.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a 2x2 grid layout to categorize sustainability initiatives.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The pyramid uses product imagery as the background fill.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a visual collage approach to demonstrate brand engagement strategies.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
11
The slide uses visual examples of product collaborations to demonstrate brand strategy.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
12
The slide uses a grouped bar chart to show digital penetration across four regions over three years.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
13
The slide uses a grouped bar chart format to show year-over-year and two-year growth rates for four key financial metrics.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
14
Crocs | Investor Presentation Deck | 30 slidesCrocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
15
Includes a lifestyle photo of a person wearing Crocs.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
16
Crocs | Investor Presentation Deck | 30 slidesCrocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
17
The slide uses a bulleted list to highlight the business impact of a specific product line.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
18
The slide uses a color-coded system where green represents digital channels.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
19
The slide uses a celebrity endorsement image to reinforce the Asia strategy.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
20
Includes both GAAP and Non-GAAP metrics with year-over-year variance.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · FinancialsLoop · Hypothesis Test1 hit
21
Includes both GAAP and Non-GAAP metrics with year-over-year variance.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · FinancialsLoop · Hypothesis Test1 hit
22
The slide includes a photo of a Nasdaq billboard celebrating Crocs' addition to the S&P Midcap 400 index.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations Beat · FinancialsLoop · Hypothesis Test1 hit
23
Crocs | Investor Presentation Deck | 30 slidesCrocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
24
Includes footnotes explaining adjustments for new distribution centers and COVID-19 inventory write-offs.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
25
Includes footnotes explaining specific COVID-19 related adjustments.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
26
The table includes adjustments for cost of sales and SG&A expenses.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
27
Includes footnotes explaining non-GAAP adjustments and the 2020 intra-entity IP transfer.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
28
The table provides a detailed breakdown of adjustments to GAAP net income, including cost of sales, SG&A, other income, and tax effects, alongside share count adjustments.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
29
Crocs | Investor Presentation Deck | 30 slidesCrocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
30
The slide serves as a visual brand identity or transition slide.Crocs | Investor Presentation Deck | 30 slides · Crocs
Conference presentation Investor relations 1 hit
01
Slide 1
Erasca | IPO Presentation Deck | 46 slidesErasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
02
Erasca | IPO Presentation Deck | 46 slidesErasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
03
Erasca | IPO Presentation Deck | 46 slidesErasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
04
The slide combines mission statement, company history, pipeline milestones, and investor logos.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
05
Erasca | IPO Presentation Deck | 46 slidesErasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
06
The slide highlights the credibility of the company's scientific advisors.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
07
The chart uses a waterfall structure to show the cumulative total of patient lives affected across different cancer types and regions.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · ProblemLoop · Pattern Hunter1 hit
08
The table uses color coding to distinguish between market types. The 'Red ocean' cells are highlighted in red, while the rest are blue. The bottom rows show geographic totals.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · ProblemLoop · Pattern Hunter1 hit
09
The slide uses a biological signaling pathway map as a framework to explain the company's therapeutic strategy.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Solution1 hit
10
The slide uses a Gantt-style chart to represent clinical trial progress across multiple programs.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Solution1 hit
11
The slide uses a biological process diagram to map drug candidates to specific protein targets.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Solution1 hit
12
The slide uses a checkmark for owned/licensed programs and a 'P' for partnered programs, highlighting Erasca's broad coverage compared to peers.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
13
The slide uses a biological pathway diagram to illustrate the position of ERK relative to other nodes like MEK and RAF.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
14
The table uses a highlight row for the primary subject (ERAS-007) to draw focus.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
15
The chart shows a logarithmic scale for IC50 (nM) across different cell lines grouped by mutation status (BRAF, HRAS, KRAS, NRAS, wildtype).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
16
Erasca | IPO Presentation Deck | 46 slidesErasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
17
The slide uses red dashed boxes to highlight the sustained suppression of P-RSK, a marker of MAPK pathway reactivation, specifically showing ERAS-007's superior performance.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
18
The slide uses a comparative experimental design to demonstrate the superior efficacy of ERAS-007 in a specific biological pathway.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
19
Data shows efficacy of ERAS-007 in combination with Encorafenib and Cetuximab in BRAF-mutant colorectal cancer models.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
20
The slide demonstrates efficacy in two distinct models (HCC827/ER1 and NCI-H820).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
21
The slide presents preclinical efficacy data for ERAS-007 in two different KRAS-mutant cancer models.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
22
The chart displays individual patient responses (waterfall plot) categorized by dose level.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
23
The chart uses color to represent dosage and symbols to represent clinical response (Partial Response, Stable Disease, Progressive Disease).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
24
Includes patient history details (genetics, prior treatments, dosage) for two case studies.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
25
The slide highlights that QW dosing is better tolerated, specifically noting less rash and manageable side effects compared to QD dosing.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
26
The table highlights the safety profile of the drug candidate in a clinical trial setting.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank Beat · Traction1 hit
27
The slide uses a line chart to show drug concentration over time and a table to summarize key PK/PD metrics (Cmax, Cmin, T>IC90, T<IC50).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
28
The slide uses a biological pathway diagram to illustrate the mechanism of action for SHP2 inhibitors.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
29
The slide uses a table to contrast the target (SHP2) against a panel of off-target phosphatases.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
30
Includes a negative control row (A375).Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
31
IC50 values represent potency; lower values indicate higher potency.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
32
The slide presents technical pharmacological data to support the drug's viability.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
33
TGI = Tumor Growth Inhibition. Data shows mean tumor volume over time.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
34
NSCLC EGFR exon 19 deletion CDX model HCC827Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
35
CRC KRAS G12C PDX CO-04-0310 model used for efficacy and safety assessment.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit
36
The slide uses a hierarchical process flow to illustrate the progression of clinical trial cohorts.Erasca | IPO Presentation Deck | 46 slides · Erasca
Pitch deck Investment bank 1 hit